Delivery Strategies for RNA-Based Drugs in Cancer
A special issue of Non-Coding RNA (ISSN 2311-553X). This special issue belongs to the section "Clinical Applications of Non-Coding RNA".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 241
Special Issue Editor
Interests: melanoma; BRAFV600E isoforms; microRNAs; ceRNAs; pigmentation; melanoma modeling in zebrafish and mice; attenuated Listeria monocytogenes; pseudogenes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Over the last few years, substantial progress has been made towards the clinical application of RNA-based drugs, and several FDA approvals have been gained. However, the Achille’s heel of this highly versatile and potentially groundbreaking therapeutic approach remains the delivery, as the currently available systems (inorganic-based, organic-based, lipid-based, viral vectors, biological vectors) are far from optimal, preventing the clinical use of many molecules despite their potential efficacy.
Within this landscape, our Special Issue intends to collect original articles focused on new delivery strategies for anticancer RNA-based drugs. Such strategies should aim to overcome at least one of the drawbacks that are still standing, including limited loading capacity, poor specificity for cancer cells vs normal cells, and high immunogenicity.
By showcasing innovative delivery approaches, we aim to expand the field of application of RNA-based drugs, ultimately contributing to enhanced therapeutic efficacy in cancer treatment.
Dr. Laura Poliseno
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA-based drug
- delivery
- cancer
- loading capacity
- specificity
- immunogenicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
